Vaxart (VXRT) Competitors

89bio (NASDAQ:ETNB) and Vaxart (NASDAQ:VXRT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation, community ranking and media sentiment.

Do insiders & institutionals believe in ETNB or VXRT?

18.1% of Vaxart shares are held by institutional investors. 2.8% of 89bio shares are held by company insiders. Comparatively, 2.6% of Vaxart shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Do analysts prefer ETNB or VXRT?

89bio presently has a consensus target price of $30.33, suggesting a potential upside of 360.99%. Vaxart has a consensus target price of $3.00, suggesting a potential upside of 292.41%. Given 89bio's higher probable upside, research analysts clearly believe 89bio is more favorable than Vaxart.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
89bio	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Vaxart	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the MarketBeat Community prefer ETNB or VXRT?

Vaxart received 200 more outperform votes than 89bio when rated by MarketBeat users. Likewise, 65.54% of users gave Vaxart an outperform vote while only 64.33% of users gave 89bio an outperform vote.

Company	Underperform	Outperform
89bio	Outperform Votes 110 64.33%	Underperform Votes 61 35.67%
Vaxart	Outperform Votes 310 65.54%	Underperform Votes 163 34.46%

Which has more risk & volatility, ETNB or VXRT?

89bio has a beta of 1.14, indicating that its stock price is 14% more volatile than the S&P 500. Comparatively, Vaxart has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500.

Which has higher earnings & valuation, ETNB or VXRT?

Vaxart has higher revenue and earnings than 89bio. 89bio is trading at a lower price-to-earnings ratio than Vaxart, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
89bio	N/A	N/A	-$142.19M	-$2.91	-2.26
Vaxart	$7.38M	23.56	-$82.46M	-$0.41	-1.86

Does the media prefer ETNB or VXRT?

In the previous week, 89bio had 13 more articles in the media than Vaxart. MarketBeat recorded 17 mentions for 89bio and 4 mentions for Vaxart. Vaxart's average media sentiment score of 0.54 beat 89bio's score of 0.14 indicating that Vaxart is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
89bio	5 Very Positive mention(s)	4 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Vaxart	0 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is ETNB or VXRT more profitable?

89bio has a net margin of 0.00% compared to Vaxart's net margin of -431.61%. 89bio's return on equity of -59.58% beat Vaxart's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
89bio	N/A	-59.58%	-52.21%
Vaxart	-431.61%	-110.46%	-62.78%

Summary

89bio and Vaxart tied by winning 9 of the 18 factors compared between the two stocks.